Effects of chronic inhibition of inducible nitric oxide synthase in hyperthyroid rats

American Journal of Physiology - Endocrinology and Metabolism

Volumn 288, Issue 6 51-6, 2005, Pages

  Rodríguez Gómez, Isabel ^a   Wangensteen, Rosemary ^a   Moreno, Juan Manuel ^b   Chamorro, Virginia ^a   Osuna, Antonio ^b   Vargas, Félix ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Aminoguanidine; Blood pressure; Rat; Thyroxine

Indexed keywords

AMINOGUANIDINE; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; THYROXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CHRONICITY; CONTROLLED STUDY; ENZYME INHIBITION; HEART RATE; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HOMEOSTASIS; HYPERTENSION; HYPERTHYROIDISM; KIDNEY HYPERTROPHY; MALE; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; PULSE PRESSURE; RAT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; BLOOD CHEMICAL ANALYSIS; BLOOD PRESSURE; BODY WEIGHT; ENZYME INHIBITORS; GUANIDINES; HEART RATE; HYPERTHYROIDISM; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; ORGAN SIZE; RANDOM ALLOCATION; RATS; RATS, WISTAR; THYROXINE; URINALYSIS;

EID: 19444371861     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00279.2004     Document Type: Article

References (39)

1. Ahn KY, Mohaupt MG, Madsen KH, and Kone BC. In situ hybridization localization of mRNA encoding inducible nitric oxide synthase in rat kidney. Am J Physiol Renal Fluid Electrolyte Physiol 267: F748-F757, 1994.
2. Bedotto JB, Gay RG, Graham SD, Morkin E, and Goldman S. Cardiac hypertrophy induced by thyroid hormone is independent of loading conditions and beta adrenoceptor blockade. J Pharmacol Exp Ther 248: 632-636, 1989.
3. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
4. Bradley SE, Stephan F, Coelho JB, and Reville P. The thyroid and the kidney. Kidney Int 6: 346-365, 1974.
5. Corbett JA, Tilton RA, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster JR Jr, Williamson JR, and McDaniel ML. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevent diabetic vascular dysfunction. Diabetes 41: 552-556, 1992.
6. Cowley AW, Mattson DL, Lu S, and Roman RJ. The renal medulla and hypertension. Hypertension 25: 663-673, 1995.
7. Crijns FRL, Struijker Boudier HAJ, and Wolffenbuttel BHR. Arteriolar reactivity in conscious diabetic rats. Influence of aminoguanidine treatment. Diabetes 47: 918-923, 1998.
8. Deng AY and Rapp JP. Locus for the inducible, but not a constitutive, nitric oxide synthase cosegregates with blood pressure in the salt sensitive Dahl rats. J Clin Invest 95: 2170-2177, 1995.
9. Fernández V, Cornejo P, Tapia G, and Videla LA. Influence of hyperthyroidism on the activity of liver nitric oxide synthase in the rat. Nitric Oxide 1: 463-468, 1997.
10. Fujihara CZ, Mattar AL, Vieira JM, Malheiros DM, Noronha IL, Goncalves AR, Nucci G, and Zatz R. Evidence for the existence of two distinct functions for the inducible NO synthase in the rat kidney: effect of aminoguanidine in rats with 5/6 ablation. J Am Soc Nephrol 13: 2278-2287, 2002.
11. García del Río C, Moreno MRR, Osuna A, Luna JD, García-Estañ J, and Vargas F. Role of the renin-angiotensin system in the development of thyroxine-induced hypertension. Eur J Endocrinol 136: 656-660, 1997.
12. Gardiner SM, Compton AM, Bennett T, Palmer RMJ, and Moncada S. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 15: 486-492, 1990.
13. Granger DL, Taintor RR, Boockvar KS, and Hibbs JB. Measurement of nitrate and nitrite in biochemical samples using nitrate reductase and Griess reaction. Methods Enzymol 268: 142-151, 1996.
14. Griffiths MJD, Messent M, MacAllister RJ, and Evans TW. Amino-guanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol 110: 963-968, 1993.
15. Hong HJ, Loh SH, and Yen MH. Suppression of the development of hypertension by the inhibitor of inducible nitric oxide sinthase. Br J Pharmacol 131: 631-637, 2000.
16. Kita Y, Muramoto M, Fujikawa A, Yamazaki T, Notsu Y, and Nishimura S. Discovery of novel inhibitors of inducible nitric oxide synthase. J Pharm Pharmacol 54: 1141-1154, 2002.
17. Klein I and Ojamaa K. Thyroid hormone and blood pressure regulation. In: Hypertension: Pathophysiology, Diagnosis and Management (2nd ed.), edited by Laragh JH and Brenner BN. New York: Raven, 1995, p. 2247-2262.
18. Klein I. Thyroid hormone and the cardiovascular system. Am J Med 88: 631-637, 1990.
19. Larsen PR, Davis TF, and Hay ID. The thyroid gland. In: Williams Textbook of Endocrinology (6th ed.), edited by Wilson ID, Foster DW, Kronenberg HK, and Larsen PR. London: Saunders, 1998, p. 389-515.
20. Li YM, Steffes M, Donnelly T, Liu C, Fuh H, Basgen J, Bucala R, and Vlassara H. Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci USA 93: 3902-3907, 1996.
21. Mattson DL, Maeda CY, Bachman TD, and Cowley AW Jr. Inducible nitric oxide synthase and blood pressure. Hypertension 31: 15-20, 1998.
22. Misko TP, Moore WM, Kasten TP, Nickols GA, Corbett JA, Tilton RG, McDaniel ML, Williamson JR, and Currie MG. Selective inhibition of inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 233: 119-125, 1993.
23. Moncada S, Palmer RMJ, and Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43: 109-142, 1991.
24. Morgan HE and Baker KM. Cardiac hypertrophy: mechanical, neural, and endocrine dependence. Circulation 83: 13-25, 1991.
25. Ortíz MC, Fortepiani LA, Martínez C, Atucha NM, and García-Estañ J. Renal and pressor effects of aminoguanidine in cirrhotic rats with ascites. J Am Soc Nephrol 7: 2694-2699, 1996.
26. Quesada A, Sainz J, Wangensteen R, Rodríguez-Gómez I, Vargas F, and Osuna A. Nitric oxide synthase activity in hyperthyroid and hypothyroid rats. Eur J Endocrinol 147: 117-122, 2002.
27. Rodríguez-Gómez I, Sainz J, Wangensteen R, Moreno JM, Duarte J, Osuna A, and Vargas F. Increased pressor sensitivity to chronic nitric oxide deficiency in hyperthyroid rats. Hypertension 42: 220-225, 2003.
28. Romero JC, Lahera V, Salom MG, and Biondi ML. Role of the endothelium-dependent relaxing factor nitric oxide on renal function. J Am Soc Nephrol 2: 1371-1387, 1992.
29. Sarthy DY and Kern TS. Interaction between NO and COX pathways in retinal cells to elevated glucose and retina of diabetic rats. Am J Physiol Regul Integr Comp Physiol 287: R735-R741, 2004.
30. Stoos BA, García NH, and Garbin JL. Nitric oxide inhibits sodium reabsortion in the isolated perfused cortical collecting duct. J Am Soc Nephrol 6: 89-94, 1995.
31. Sugimoto H, Shikata K, Wada J, Horiuchi S, and Makino H. Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-α and inducibie nitric oxide synthase in diabetic rat glomeruli. Diabetologia 42: 878-886, 1999.
32. Tan DY, Meng S, Cason GW, and Manning RD Jr. Mechanisms of salt sensitive hypertension: role of inducible nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 279: R2297-R2303, 2000.
33. Tanwani LK, Lohano V, Broadstone VL, and Mokshagundam SP. Minimal change nephropathy and Graves' disease: report of a case and review of the literature. Endocr Tract 8: 40-43, 2002.
34. Thorup C and Persson AEG. Nitric oxide and renal blood pressure regulation. Curr Opin Nephrol Hypertens 7: 197-202, 1998.
35. Tsukahara H, Hiraoka M, Kobata R, Hata I, Oshima Y, Jiang MZ, Niori E, and Mayumi M. Increased oxidative stress in rats with chronic nitric oxide depletion: measurement of urinary 8-hydroxy-2′-deoxyguanosine excretion. Redox Rep 5: 23-28, 2000.
36. Vargas F, Atucha N, Sabio JM, Quesada T, and García-Estañ J. Pressure-diuresis-natriuresis response in hyper- and hypothyroid rats. Clin Sci (Colch) 87: 323-328, 1994.
37. Vargas F, Baz MJ, Luna JD, Andrade J, Jodar E, and Haro JM. Urinary excretion of digoxin-like immunoreactive factor and arginine vasopressin in hyper- and hypothyroid rats. Clin Sci (Colch) 81: 471-476, 1991.
38. Weetman AP, Tomlinson K, Amos N, Lazarus JH, Hall R, and McGregor AM. Proteinuria in autoimmune thyroid disease. Acta Endocrinol 109: 341-347, 1985.
39. 1 mice. Clin Exp Immunol 113: 258-264, 1998.